Evommune, Inc. Insider Trading

EVMN

⊜ Compare

Last 12 months

Insiders bought $25.2M and sold $2.28M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+$22.9M

4 buys · 8 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

4 / 6

executives and directors

Last open-market buy

Jul 2026

Jul 8, 2026

Get an email when EVMN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 8	Kyle Carver Chief Financial Officer	Bought	1,000	$13.26	13K	1.7%	Form 4
Jul 7	Arthur S Kirsch Director	Bought	10,000	$13.30	133K	New	Form 4
Jun 22	Jeegar Pravinkumar Patel Chief Scientific Officer	Sold10b5-1 plan	1,488	$22.50	33K	3.1%	Form 4
Jun 22	Janice Suzann Drew Chief of Dev. Operations	Sold10b5-1 plan	20,000	$22.63	453K	23%	Form 4
Jun 22	Luis C. Pena President & CEO	Sold10b5-1 plan	7,438	$22.71	169K	1.2%	Form 4
Jun 2	David E Cohen Director	Sold10b5-1 plan 2 parts	6,056	$20.33 average	123K	26%	Form 4
Jun 1	Jeegar Pravinkumar Patel Chief Scientific Officer	Sold10b5-1 plan	16,687	$22.74	379K	26%	Form 4
Jun 1	Luis C. Pena President & CEO	Sold10b5-1 plan	16,787	$22.74	382K	2.6%	Form 4
May 28	Kyle Carver Chief Financial Officer	Sold10b5-1 plan	18,175	$22.84	415K	23%	Form 4
May 28	Gregory S. Moss Chief Business & Legal Officer	Sold10b5-1 plan	14,223	$22.83	325K	18%	Form 4
Dec 19, 2025	Robert Lorne Hopfner Director	Bought	1,000	$17.35	17K	<0.1%	Form 4
Nov 7, 2025	Weegen Felice Isabel Verduyn-Van Director	Bought	1,562,500	$16.00	$25M	46%	Form 4
Nov 7, 2025	7 Cooperative Ua Lsp Large holder	Bought	1,562,500	$16.00	$25M	46%	Form 4
Nov 7, 2025	RA Capital Management, L.p. Large holder	Bought 2 parts	1,250,000	$16.00 average	$20M	New	Form 4

Jul 8
Kyle Carver
Chief Financial Officer · bought 1,000 at $13.26
13K
1.7% of stake
Jul 7
Arthur S Kirsch
Director · bought 10,000 at $13.30
133K
New position
Jun 2210b5-1 plan
Jeegar Pravinkumar Patel
Chief Scientific Officer · sold 1,488 at $22.50
33K
3.1% of stake
Jun 2210b5-1 plan
Janice Suzann Drew
Chief of Dev. Operations · sold 20,000 at $22.63
453K
23% of stake
Jun 2210b5-1 plan
Luis C. Pena
President & CEO · sold 7,438 at $22.71
169K
1.2% of stake
Jun 210b5-1 plan
David E Cohen
Director · sold 6,056 at avg $20.33
123K
26% of stake
Jun 110b5-1 plan
Jeegar Pravinkumar Patel
Chief Scientific Officer · sold 16,687 at $22.74
379K
26% of stake
Jun 110b5-1 plan
Luis C. Pena
President & CEO · sold 16,787 at $22.74
382K
2.6% of stake
May 2810b5-1 plan
Kyle Carver
Chief Financial Officer · sold 18,175 at $22.84
415K
23% of stake
May 2810b5-1 plan
Gregory S. Moss
Chief Business & Legal Officer · sold 14,223 at $22.83
325K
18% of stake
Dec 19, 2025
Robert Lorne Hopfner
Director · bought 1,000 at $17.35
17K
<0.1% of stake
Nov 7, 2025
Weegen Felice Isabel Verduyn-Van
Director · bought 1,562,500 at $16.00
$25M
46% of stake
Nov 7, 2025
7 Cooperative Ua Lsp
Large holder · bought 1,562,500 at $16.00
$25M
46% of stake
Nov 7, 2025
RA Capital Management, L.p.
Large holder · bought 1,250,000 at avg $16.00
$20M
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EVMN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with EVMN

CompareIntrinsic value

ZBIOZenas BioPharma, Inc.

$28.46+0.28%10

PGENPrecigen Inc.

$5.06-3.71%0

BIOABioAge Labs, Inc.

$5.95-0.17%10

HOOKHookipa Pharma Inc.

No recent price20

ISCOInternational Stem Cell Corporation

$0.14+0.00%29

CBIOCrescent Biopharma, Inc.

$13.42+2.76%50

ALMSAlumis Inc.

$6.55+0.77%10

ROIVRoivant Sciences Ltd

$38.23+6.08%16

Held by ETFs

EVMN is in 11 US ETFs. The largest of them, with EVMN's weight in each:

Spot a number that looks wrong? Check it in EVMN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EVMN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.